Health and Fitness Health and Fitness
Mon, August 2, 2010
Fri, July 30, 2010
Thu, July 29, 2010
Wed, July 28, 2010
Tue, July 27, 2010
Mon, July 26, 2010
Fri, July 23, 2010
Thu, July 22, 2010
Wed, July 21, 2010
Tue, July 20, 2010
[ Tue, Jul 20th 2010 ] - Market Wire
00 AM EDT
Mon, July 19, 2010
Sun, July 18, 2010
Sat, July 17, 2010
Fri, July 16, 2010
Thu, July 15, 2010
Wed, July 14, 2010
Tue, July 13, 2010

GenMark Diagnostics Schedules Second Quarter Earnings Release and Conference Call for August 9, 2010


//health-fitness.news-articles.net/content/2010/ .. lease-and-conference-call-for-august-9-2010.html
Published in Health and Fitness on Thursday, July 22nd 2010 at 4:11 GMT by Market Wire   Print publication without navigation


CARLSBAD, Calif.--([ BUSINESS WIRE ])--GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its second quarter 2010 financial results after market close on Monday, August 9, 2010. Management will hold a conference call to review the company's second quarter 2010 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. website at [ www.genmarkdx.com ] under the investor webcast section and will be archived for future reference.

To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number "87984618" approximately five minutes prior to the start time.

About GenMark

GenMark, a provider of automated, multiplex molecular diagnostic testing systems, detects and measures DNA and RNA targets to diagnose disease and to optimize the treatment of patients and is focused on developing and commercializing its eSensor detection technology. GenMarka™s XT-8 System is designed to support a broad range of molecular diagnostic tests with a compact and easy-to-use workstation and self-contained, disposable test cartridges. GenMark has developed four diagnostic tests for use with the XT-8 System, including its Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test and Thrombophilia Risk Test which have received clearance from the Food and Drug Administration.


Publication Contributing Sources